Cilofexor

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cilofexor
Accession Number
DB15168
Type
Small Molecule
Groups
Investigational
Description

Cilofexor is under investigation in clinical trial NCT02943447 (Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis).

Structure
Thumb
Synonyms
Not Available
External IDs
GS-9674
Categories
Not Available
UNII
YUN2306954
CAS number
1418274-28-8
Weight
Average: 586.85
Monoisotopic: 585.0625039
Chemical Formula
C28H22Cl3N3O5
InChI Key
KZSKGLFYQAYZCO-UHFFFAOYSA-N
InChI
InChI=1S/C28H22Cl3N3O5/c29-20-2-1-3-21(30)24(20)25-18(26(39-33-25)15-4-5-15)12-38-17-6-7-19(22(31)11-17)28(37)13-34(14-28)23-10-16(27(35)36)8-9-32-23/h1-3,6-11,15,37H,4-5,12-14H2,(H,35,36)
IUPAC Name
2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy}phenyl)-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid
SMILES
OC(=O)C1=CC=NC(=C1)N1CC(O)(C1)C1=C(Cl)C=C(OCC2=C(ON=C2C2=C(Cl)C=CC=C2Cl)C2CC2)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
68007315

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentNonalcoholic Steatohepatitis (NASH)2
1RecruitingTreatmentCompensated liver disease / Primary Sclerosing Cholangitis (PSC)1
2Active Not RecruitingTreatmentNonalcoholic Steatohepatitis1
2Active Not RecruitingTreatmentPrimary Sclerosing Cholangitis (PSC)1
2CompletedTreatmentNonalcoholic Steatohepatitis1
2CompletedTreatmentNonalcoholic Steatohepatitis (NASH)1
2CompletedTreatmentPrimary Biliary Cholangitis1
2RecruitingTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD) / Nonalcoholic Fatty Liver Disease (NAFLD) / Nonalcoholic Steatohepatitis (NASH)1
3RecruitingTreatmentPrimary Sclerosing Cholangitis (PSC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0295 mg/mLALOGPS
logP5.36ALOGPS
logP4.65ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)0.45ChemAxon
pKa (Strongest Basic)8.14ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area108.92 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity148.43 m3·mol-1ChemAxon
Polarizability56.81 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:55 / Updated on March 01, 2020 22:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates